


**Product Name** : CA-170  
**Cat. No.** : PC-72654  
**CAS No.** : 1673534-76-3  
**Molecular Formula** : C<sub>12</sub>H<sub>20</sub>N<sub>6</sub>O<sub>7</sub>  
**Molecular Weight** : 360.33  
**Target** : PD-1/PD-L1  
**Solubility** : 50 mM in DMSO (18.1 mg/mL)



## Biological Activity

CA-170 (CA170) is a first-in-class, orally available, tripeptide small-molecule dual antagonist of **VISTA/PD-L1**, important negative checkpoint regulators of immune activation.

CA-170 demonstrated dose-dependent enhancement in the proliferation of PD-L1, PD-L2, and VISTA-inhibited T lymphocytes, and exhibited antitumor effects similar to those of antibodies, including tumor shrinkages and prolonged stable disease without adverse effects.

CA170 has excellent oral bioavailability, a relatively short half-life, and it can dose-dependently enhance the proliferation of T lymphocytes due to its ability to inhibit VISTA.

In syngeneic murine tumor models, the antitumor effects of CA170 were similar to VISTA-blocking antibody.

CA170 was well tolerated in phase I clinical trials and is undergoing phase II clinical trials for lung cancer, head and neck/oral cavity cancer, MSI-H positive cancers, and Hodgkin lymphoma.

## References

Musielak B, et al. *Molecules*. 2019 Aug 1;24(15):2804.

Sasikumar PG, et al. *Commun Biol*. 2021 Jun 8;4(1):699.

Li TT, et al. *BMC Immunol*. 2021 Aug 11;22(1):55.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com